Current Antipsychotics
Six decades after the serendipitous discovery of chlorpromazine as an antipsychotic and four decades after the launch of clozapine, the first atypical or second generation antipsychotic, psychopharmacology has arrived at an important crossroad. It is clear that pharmacological research and pharmaceu...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Weitere Verfasser: | |
| Dokumenttyp: | Edited Volume |
| Sprache: | Englisch |
| Veröffentlicht: |
Berlin Heidelberg
Springer
2012
|
| Schriftenreihe: | Handbook of Experimental Pharmacology
212 SpringerLink Bücher |
| Volumes / Articles: | Show Volumes / Articles. |
| DOI: | 10.1007/978-3-642-25761-2 |
| Schlagworte: | |
| Online-Zugang: | Verlag, Volltext: https://doi.org/10.1007/978-3-642-25761-2 Resolving-System, lizenzpflichtig, Volltext: http://dx.doi.org/10.1007/978-3-642-25761-2 Cover: https://swbplus.bsz-bw.de/bsz376064994cov.jpg Verlag, Inhaltsverzeichnis: http://d-nb.info/1016844328/04 Verlag, Inhaltstext: http://deposit.dnb.de/cgi-bin/dokserv?id=3905507&prov=M&dok_var=1&dok_ext=htm 
|
| Verfasserangaben: | edited by Gerhard Gross, Mark A. Geyer |
Inhaltsangabe:
- Current Antipsychotics; Preface; Contents; Contents of Volume 213; The Dopamine Dysfunction in Schizophrenia Revisited: New Insights into Topography and Course; 1 Introduction; 2 Evidence for Dopamine (DA) Dysfunction in Schizophrenia; 2.1 Striatal DA Alterations; 2.1.1 Presynaptic DAergic Parameters; Dopamine Synthesis; Dopamine Release; Dopamine Reuptake; 2.1.2 Postsynaptic DAergic Parameters; DA Receptor Availability; Balance in D2 Receptor Affinity States; 2.2 Extrastriatal DA Alterations; 2.3 Prefrontal Cortical DA Alterations; 2.4 Dopamine in At-Risk and Prodromal States; 2.5 Summary
- 3 Functional and Clinical Implications3.1 Relating DA Dysfunction to Positive Symptoms; 3.2 Relating DA Dysfunction to Negative and Cognitive Symptoms; 3.3 Neural Circuitry; the Interdependence of Dopaminergic, Glutamatergic, and GABAergic Processes; 4 Conclusions; References; Role of Dopamine D2 Receptors for Antipsychotic Activity; 1 Introduction; 1.1 Role of Dopamine in the Pathophysiology of Schizophrenia; 1.1.1 Dopamine Receptor Studies in Schizophrenia; Dopamine Presynaptic Dysregulation in Schizophrenia; 2 Mechanism of Antipsychotic Action; 2.1 Antipsychotic Treatment
- 2.2 Role of D2 Receptor Blockade2.2.1 Role of Non-D2 Receptor Blockade; Preferential Limbic D2 Receptor Blockade; Transient Versus Continuous D2 Receptor Blockade; 3 Mechanisms Underlying Speed and Onset of Antipsychotic Response; 4 Linking Dopaminergic Disturbances, Psychology and Pharmacology in Schizophrenia; 5 Conclusion and Future Directions; References; Dopamine Receptor Signaling and Current and Future Antipsychotic Drugs; 1 Introduction; 1.1 Background on Dopamine Receptors; 1.2 Dopamine Receptors and Antipsychotic Drug Action; 1.3 Dopamine Receptors and Functional Selectivity
- 1.4 Allosteric Targeting of Dopamine Receptors2 D2-Like Signaling; 2.1 Evidence for Functional Selectivity at D2-Like Receptors; 2.1.1 Hypothesized Presynaptic/Autoreceptor Selective Ligands and Functional Selectivity; 2.1.2 Early Evidence for the Functional Selectivity of Dopaminergic Compounds; 2.1.3 Functional Selectivity In Vitro Affects Pharmacological Effects In Vivo; 2.1.4 D2 Functionally Selective Drugs and Schizophrenia; 3 D1-Like Signaling; 3.1 Evidence for Functional Selectivity at D1-Like Receptors
- 3.1.1 Possible Mechanisms of D1-Receptor Signaling That Could Evoke Functional Selectivity3.1.2 Phospholipase C as a D1 Signaling Mechanism; 3.1.3 Implications and Complications of Purported D1-Mediated PLC Signaling; 3.1.4 Direct Evidence for Functional Selectivity at the D1-Like Receptors; 3.1.5 Potential Utility of D1 Functionally Selective Drugs; 4 Conclusion; References; Serotonergic Mechanisms as Targets for Existing and Novel Antipsychotics; 1 Introduction; 2 The 5-HT2A Receptor as a Target for Antipsychotic Drug Action; 2.1 Neurobiology of 5-HT2A Receptors
- 2.2 Central Effects of Selective 5-HT2A Antagonists